首页|低分子肝素预防产褥期静脉血栓栓塞性疾病的药物治疗管理效果

低分子肝素预防产褥期静脉血栓栓塞性疾病的药物治疗管理效果

扫码查看
目的 基于药物治疗管理(MTM)探讨低分子肝素对产褥期静脉血栓栓塞性疾病(VTE)预防的疗效和安全性.方法 选取2021年1月至2022年12月收治的139例产妇,随机分为常规治疗组68例和MTM组71例.根据VTE风险评分,将常规治疗组分为中危常规治疗组(37例)和高危常规治疗组(31例),将MTM组分为中危MTM组(38例)和高危MTM组(33例).比较4组用药前后凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)和D-二聚体(D-D)]、血小板(PLT)计数、肝肾功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Scr)]及不良反应发生情况.结果 中危MTM组和中危常规治疗组用药1 d后PT、APTT和AST水平均高于用药前(P<0.01).中危MTM组用药1 d后D-D低于中危常规治疗组(P<0.05).高危MTM组和高危常规治疗组用药7 d后D-D低于用药前,用药7d后APTT、PLT计数、ALT和AST水平高于用药前,FIB水平低于用药前(P<0.05).中危MTM组共发生不良反应1例,高危MTM组共发生不良反应3例,高危常规治疗组共发生不良反应7例.中危MTM组的疾病认知度低于高危MTM组(P<0.01).接受MTM后高危MTM组的用药依从性提高(P<0.01).结论 低分子肝素能够改善产褥期产妇高凝状态,长期使用需关注对肝功能及凝血功能的影响.MTM能够提高VTE的防治水平、产妇对疾病的认知度和用药依从性.
Analysis of effects of low-molecular-weight heparin in the prevention of puerperal venous thromboembolism based on medication therapy management
AIM To explore the efficacy and safety of low-molecular-weight heparin in the prevention of venous thromboembolism(VTE)based on medication therapy management(MTM).METHODS From January 2021 to December 2022,a total of 139 participants were stratified by VTE risk score and randomly divided into 4 groups:medium-risk conventional treatment group(37 patients),medium-risk MTM group(38 patients),high-risk conventional treatment group(31 patients)and high-risk MTM group(33 patients).All results were compared within 4 groups before and after using medication,including coagulation function[activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB),D-dimer(D-D)],platelet(PLT)count,liver and kidney function[alanine aminotransferase(ALT),glutamic oxalacetic transaminase(AST),creatinine(Scr)]and adverse reactions.RESULTS PT and APTT were prolonged in 2 medium-risk groups(P<0.01)after a day of medication.After a day of medication,the D-D level in the medium-risk MTM group was lower than that in the medium-risk conventional treatment group(P<0.05).After 7 days of medication,the D-D levels in both the high-risk MTM group and the high-risk conventional treatment group were lower than prior medication.Increased APTT,PLT counts and ALT levels could be observed in 2 high-risk groups after 7 days of medication.AST level was increased in all groups after medication(P<0.05).At the same time,the level of FIB was decreased(P<0.05).There was a case of adverse reaction in the medium-risk MTM group.There were 3 cases of adverse reactions in the high-risk MTM group and 7 cases in the high-risk conventional treatment group.The medium-risk MTM group exhibited a lower degree of disease awareness than the high-risk MTM group(P<0.01).Following the implementation of MTM,an enhancement in medication adherence was observed within the high-risk MTM group(P<0.01).CONCLUSION Low-molecular-weight heparin can significantly improve the coagulation function during the puerperal period,and its long-term use requires attention to be paid to its effects on liver function and coagulation function.The prevention and treatment level of VTE can be improved by MTM,as well as the disease awareness and medication compliance of parturient women.

low-molecular-weight heparinpuerperal periodvenous thromboembolismmedication therapy management

陈芸萱、周慧、肖春、王朝、周慧民、许厚钦、杨志文

展开 >

上海市长宁区妇幼保健院药剂科,上海 200051

上海市长宁区妇幼保健院产科,上海 200051

低分子肝素 产褥期 静脉血栓栓塞症 药物治疗管理

上海市长宁区医疗卫生科研专项课题

CNKW2020Y30

2024

中国临床药学杂志
中国药学会

中国临床药学杂志

CSTPCD
影响因子:0.502
ISSN:1007-4406
年,卷(期):2024.33(9)